stockrow
Friday 6 November 2026
Export ICU’s income statement to Excel — free account
SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, up 814.1% from fiscal 2024.
- Revenue
- +82.0%
- EPS
- +49.4%
- Free cash flow
- +0.43%
Quarter to June 2026, against a year earlier
1.91
0.01
−0.52%
Follow ICU
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 0 | 1 | 2 | +814.1% | 2 | 3 | 16 | +134.9% | |
| Gross margin, % | — | — | — | — | — | — | — | — | 100.00 | 95.71 | 92.64 | (4.3) pt | ||||||
| EBT | — | — | — | — | 0 | (5) | (12) | (26) | (25) | (12) | (14) | +371.7% | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (18,390.37) | (984.36) | (795.33) | (984.4) pt | ||||||
| Net income | — | 0 | — | — | 0 | (5) | (12) | (26) | (25) | (12) | (14) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.36 | 0.60 | 0.42 | n/m | |||||
| Earnings | — | — | — | — | (0.61) | (158.72) | (371.15) | (302.50) | (66.30) | (5.86) | (3.91) | +57.4% | ||||||
| Cash flow | — | — | — | — | (13.14) | (176.34) | (237.62) | (118.63) | (42.80) | (6.56) | (3.35) | (13.0%) | ||||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | (13.14) | (176.34) | (237.62) | (118.63) | (42.80) | (6.56) | (3.35) | (13.0%) | ||||||
| Book value | — | — | — | — | 2.30 | (97.10) | (632.99) | (159.98) | (5.84) | 5.02 | 1.05 | +16.9% | ||||||
| Shares, m | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 2 | 3 | +199.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 4.03 | 4.55 | 2.0 | ||||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | 0.48 | 1.82 | 0.2 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | (3.60) | 1.99 | (1.8) | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | (0.50) | 0.33 | (0.25) | (0.1) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (5) | (8) | (10) | (16) | (14) | (14) | +160.7% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | 0 | (5) | (8) | (10) | (16) | (14) | (14) | +160.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | (3) | (15) | (11) | (3) | 10 | 4 | n/m | |||||
| Net debt | — | — | — | — | 0 | 0 | 8 | 4 | (2) | (12) | (7) | +215.4% | ||||||
| Shareholders’ equity | — | — | — | — | 0 | (3) | (21) | (14) | (2) | 10 | 4 | +250.1% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | (1.93) | (1,053.89) | (669.60) | (800.85) | (607.76) | (129.15) | (160.02) | (127.2) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | (26.26) | 328.73 | 103.40 | 151.49 | 309.35 | (295.15) | (356.87) | (268.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 2 | 2 | 9 | 12 | 19 | 17 | — | +53.4% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.07 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
SeaStar Medical Holding Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CLRB Cellectar Biosciences, Inc. | $10.9M | — (loss-making) | — | −73.23% (below 0%: shrinking) | n/m | −17.49% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LSTA Lisata Therapeutics, Inc. | $10.7M | — (loss-making) | — (loss-making) | −98.30% (below 0%: shrinking) | n/m | +33.04% (above 0%: growing) | 100.00% | 0.00% | Compare |
| GDTC CytoMed Therapeutics Limited | $10.4M | — (loss-making) | — (loss-making) | — | n/m | −27.39% (below 0%: shrinking) | 0.00% | — | Compare |
| BIVI BioVie Inc. | $10.3M | — (loss-making) | — | — | n/m | +26.50% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ICU SeaStar Medical Holding Corporation | $10.2M | — (loss-making) | — (loss-making) | +81.95% (above 0%: growing) | n/m | +0.43% (above 0%: growing) | 91.22% | (616.42%) | |
| PTN Palatin Technologies, Inc. | $10.2M | 13.6× | 0.2× | −14.06% (below 0%: shrinking) | n/m | +34.21% (above 0%: growing) | 100.00% | (1,469.35%) | Compare |
| INTS Intensity Therapeutics Inc. | $10.1M | — (loss-making) | — | — | n/m | +4.72% (above 0%: growing) | 0.00% | 0.00% | Compare |
| AZR Azora Therapeutics, Inc. | $9.7M | — (loss-making) | — | — | n/m | −263.66% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GTBP GT Biopharma, Inc. | $9.4M | 0.8× | — | −100.00% (below 0%: shrinking) | n/m | −41.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $10.2M | — | — | −85.76% | — | −6.38% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 29 April 2026
Ownership
Directors and executive officers, together
less than 1%
Intracoastal Capital, LLC
9.99%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement